Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.
Trimethoprim-sulfamethoxazole is the preferred agent for prophylaxis against Pneumocystis jiroveci pneumonia. Alternative agents are used in treating patients who do not tolerate this medication. We report 2 cases of prophylaxis failure in patients receiving low-dose atovaquone. We discuss the use of atovaquone as an alternative agent for prophylaxis in transplant recipients.
Rodriguez
Martin
M
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Sifri
Costi D
CD
Fishman
Jay A
JA
D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D053626:Atovaquone; D018890:Chemoprevention; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009285:Naphthoquinones / Q000627:therapeutic use*; D009894:Opportunistic Infections / Q000382:microbiology / Q000517:prevention & control*; D045363:Pneumocystis carinii / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D017211:Treatment Failure; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000935:Antifungal Agents; D009285:Naphthoquinones; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D053626:Atovaquone